The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Genetic counseling for germline mutations and for somatic mutations have both grown exponentially in the last decades. Leading oncologists and genetics stakeholders strongly recommend that qualified oncology providers conduct predictive genetic testing. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.
Continuing Education Language
In support of improving patient care, this activity has been planned and implemented by the Society of Gynecologic Oncology (SGO) and the Advanced Practitioner Society for hematology and Oncology (APSHO). Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. SGO designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits™ , ANCC or 0.15 CEU for ACPE credits.
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS (AAPA)
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™, from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this activity.
Enduring activity: Start date: October 17, 2017; Expiration date October 16, 2018
For successful completion of the continuing education activity, participants must complete the post test with a passing score of 66% and an evaluation.
Pharmacy Universal Activity Number: 0594-0000-17-004-H01-P (knowledge based activity).; 0.15 CEU.
The pharmacists must submit their NABP ePID and DOB to the provider by after completing the online post test and evaluation.
A continuing education activity or nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists and physicians.
All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Society of Gynecologic Oncology identified and resolved all conflicts of interest through mechanisms included in the SGO’s Conflict of Interest Resolution Policy.
Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Heather Hampel has received consulting fees/honoraria from Beijing Genomics, has equity interests/stock options and has served on the advisory board for Genome Medical, has served on the advisory board for Invitae, and has a financial relationship with Myriad Genetic Labs, Inc.
Paula Anastasia has served on speakers bureaus for Clovis, Genentech, and Merck.
Brianna Hoffner has served as a consultant for Abbott Laboratories, Lilly, and Merck.
Leigha Senter-Jamieson has received consulting fees/honoraria from AstraZeneca, Clovis, and MyGene Counsel; and has served on speakers bureaus for FORCE, LBBC, and AstraZeneca.
Society of Gynecologic Oncology
Teri Jordan, CAE, CMP, has nothing to disclose.
LEAD NURSE PLANNER
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Patricia McLafferty has nothing to disclose.
Larry Rosenberg has nothing to disclose.
Lynn Rubin has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Annie Yueh has nothing to disclose.
This activity is supported with an educational grant by AstraZeneca.